Zhejiang Ausun Pharmaceutical Co Ltd (603229.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100002XK2
Zhejiang Ausun Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 795.29 m CNY | 792.76 m CNY |
| Gross profit | 421.90 m CNY | 424.20 m CNY |
| Operating income | 241.14 m CNY | 138.63 m CNY |
| EBIT | 185.71 m CNY | 145.99 m CNY |
| Net income | 206.79 m CNY | 130.57 m CNY |
| Diluted EPS – continuing operations | 0.25 CNY | 0.16 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customized contract research, development, and manufacturing services. In addition, the company engages in technology research and development, commissioned technology development, technology transfer, consulting, and promotion services; wholesale of organic intermediates; medical research and experimental development; market research; conference services; organization of exhibitions and displays; import and export trade of pharmaceuticals, food, cosmetics, medical devices, goods and technology, and related instruments and equipment; drug clinical trials; retail of pharmaceuticals; technical consultation and exchange; health consultation; and research and development of biochemical products. Zhejiang Ausun Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Taizhou, China.
More stocks
- Mega Lifesciences Public Company Limited (MEGA.BK)
- Hangzhou Youngsun Intelligent (603901.SS)
- Shanghai Tongji Science&Technology Industrial Co Ltd (600846.SS)
- A G Barr PLC (BAG.L)
- GoGold Resources Inc (GGD.TO)
- Docebo Inc (DCBO.TO)
- Daishin Securities Co Ltd Pref 2 (003547.KS)
- ASTEC INDUSTRIES INC (ASTE)
- Terveystalo Oyj (TTALO.HE)
- Logwin AG SA (TGHN.DE)
- Power HF Co Ltd (605100.SS)
- XiAn ChenXi Aviation Technology Corp Ltd (300581.SZ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.